Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 8/20 | 0.42 |
| ▸ | CDK9 | P50750 | 8/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.41 |
| ▸ | MET | P08581 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ROS1 | P08922 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661278 | 1.00 | CDK7 (0.42) | CDK7CDK9ALKMETEGFR | |
| SCHEMBL29661342 | 0.79 | CDK9 (0.43) | CDK7CDK9ALKMETEGFR | |
| SCHEMBL24327468 | 0.79 | CDK9 (0.43) | CDK7CDK9ALKMETEGFR | |
| SCHEMBL29661271 | 0.77 | CDK9 (0.42) | CDK7CDK9ALKMETEGFR | |
| SCHEMBL24327552 | 0.77 | CDK7 (0.40) | CDK7CDK9ALKEGFRLRRK2 | |
| SCHEMBL26778572 | 0.77 | CDK9 (0.42) | CDK7CDK9ALKMETEGFR | |
| SCHEMBL29661404 | 0.77 | CDK7 (0.40) | CDK7CDK9ALKEGFRLRRK2 | |
| SCHEMBL24327449 | 0.72 | ALK (0.42) | CDK7CDK9ALKEGFRLRRK2 | |
| SCHEMBL29661357 | 0.72 | ALK (0.42) | CDK7CDK9ALKEGFRLRRK2 | |
| SCHEMBL24327451 | 0.71 | CDK9 (0.40) | CDK7CDK9ALKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | CDK7 216/4885CDK9 67/4885ALK 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.